Výsledky vyhledávání

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(R)) in Patients with Metastatic Colorectal Cancer

Autor: Toshiaki Watanabe, Kensei Yamaguchi, Taku Seriu, Taroh Satoh, Megumi Ishiguro, Kenichi Sugihara, Yuh Sakata, Hideyuki Ito

Publikováno v: Japanese Journal of Clinical Oncology

Objective Cetuximab (Erbitux®) was approved for the treatment of metastatic colorectal cancer in Japan in 2008. To verify information on the safety in practical use of cetuximab, we conducted post-marketing surveillance in accordance with the condit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72bb824a050b9e3a66d5a903478e47d0
https://doi.org/10.1093/jjco/hys005

Zobrazit plný text záznamu

Markov Chain Monte Carlo Bayesian Analysis for Population Pharmacokinetics of Dasatinib in Japanese Adult Subjects with Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Autor: Hiroyuki Yoshitsugu, Masaki Hiraoka, Yasuhiko Imai, Taku Seriu

Publikováno v: Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 43:29-41

This study evaluated the population pharmacokinetics of dasatinib in Japanese subjects with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) enrolled in 3 Japa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8f0d8e575b24bfb4553c7b487811aa3
https://doi.org/10.3999/jscpt.43.29

Zobrazit plný text záznamu

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis

Autor: Taku Seriu, Nobuhiko Uoshima, Shin Fujisawa, Tadashi Nagai, S Miyawaki, Kiyoshi Ando, Masaya Okada, Masafumi Taniwaki, Ryuzo Ohno, Yukio Kobayashi, Kazuhito Yamamoto, Noriko Usui, Kenichi Ishizawa, Hisashi Sakamaki, Shinsuke Iida, Toshiko Motoji

Publikováno v: International Journal of Hematology. 93:745-749

The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had bee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90ec3b99c08deeb9468dc2a8b9354ffc
https://doi.org/10.1007/s12185-011-0864-1

Zobrazit plný text záznamu

A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

Autor: Norihito Amano, Taku Seriu, Hiroya Takiuchi, Haruhiko Imamoto, Yasuo Hamamoto, Kei Muro, Shuichi Hironaka, Ken Kato, Makoto Tahara

Publikováno v: Cancer Chemotherapy and Pharmacology. 67:1265-1272

To evaluate the efficacy and safety of weekly paclitaxel (Taxol(®)) in patients with advanced or recurrent esophageal cancer.Fifty-three patients with recurrent or advanced esophageal cancer who had previously received platinum-based chemotherapy we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897ad3d868ddecce13e867da112a6cc1
https://doi.org/10.1007/s00280-010-1422-x

Zobrazit plný text záznamu

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection

Autor: Hiroki Ishikawa, Osamu Yokosuka, Shinichi Fujioka, Taku Seriu, Michiko Shindo, Kazuaki Chayama, Haruhiko Kobashi, Kendo Kiyosawa, Norio Hayashi, Koichi Takaguchi, Chifumi Sato, Kyuichi Tanikawa, Nobuyuki Masaki, Masao Omata

Publikováno v: Journal of Hepatology. 52:791-799

To evaluate the long-term efficacy of entecavir in nucleoside-naïve chronic hepatitis B patients.One hundred and sixty-seven patients treated with entecavir 0.01mg, 0.1mg or 0.5mg for 24-52weeks in Phase II studies entered rollover study ETV-060 and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6afcbfecfda331c261173d40ed3bfc
https://doi.org/10.1016/j.jhep.2009.12.036

Zobrazit plný text záznamu

Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

Autor: Masayoshi Kage, Nobuyuki Masaki, Hiromitsu Kumada, Michio Sata, Masao Omata, Yoshiyasu Karino, Mitsuhiko Moriyama, Fumio Imazeki, Haruhiko Kobashi, Taku Seriu, Joji Toyota, Yoshiaki Katano, Namiki Izumi, Hiroki Ishikawa

Publikováno v: Hepatology International. 4:414-422

Lamivudine treatment of chronic hepatitis B (CHB) is associated with frequent resistance and loss of clinical benefit. We present outcomes of lamivudine-refractory Japanese patients treated with entecavir for 3 years.Eighty-two patients refractory to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::525e69cc6d6a206ea96c46bcbf0f371c
https://doi.org/10.1007/s12072-009-9162-x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání